Valeant bids $296M on Dendreon; AstraZeneca pairs with MD Anderson;

@FierceBiotech: Obama wants $215M to kick off 'precision medicine' project. More | Follow @FierceBiotech

@JohnCFierce: $ICPT up 38% this a.m., which is nuts. Article | Follow @JohnCFierce

@DamianFierce: The to-my-knowledge guest list for tomorrow's White House precision medicine thing: $FMI, $VRTX, $MRK, $REGN. | Follow @DamianFierce

> AstraZeneca ($AZN) signed a deal with the University of Texas' MD Anderson Cancer Center to team up on gynecologic malignancies, part of the center's Moon Shots R&D program. More

> Valeant Pharmaceuticals ($VRX) has signed a deal to acquire Dendreon ($DNDN), on the verge of bankruptcy, for $296 million. Story

> Three months after firing CEO Chris Viehbacher, Sanofi ($SNY) has yet to find a replacement, creating an embarrassing situation for the company as it prepares to present its 2014 results. News

Medical Device News

@FierceMedDev: Stomach-draining obesity startup gets $12M in debt to support PMA in mid-2015. More | Follow @FierceMedDev

@EmilyWFierce: Roche and Qualcomm join forces for next-gen remote patient monitoring system. Story | Follow @EmilyWFierce

> Wall Street buys into third med tech IPO of the week: Avinger. More

> J&J to distribute Insuline diabetes device in Russia to stem flagging diabetes care sales. News

> China medical device market to top Japan to claim No. 2 spot globally. Report

Pharma News

@FiercePharma: European regulators chart record year for new animal health products. More | Follow @FiercePharma

@EricPFierce: GSK is moving forward with its new API plant in Scotland. Story | Follow @EricPFierce

> Study of all data on Roche's highly debated Tamiflu says it does help. More

> Viehbacher's ouster, severance raise red flags for CEO candidates. News

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.